SEC Company Response from Lineage Cell Therapeutics, (LCTX) — Mar 17, 2021
Lineage Cell Therapeutics, Inc.
Date: March 17, 2021 · CIK: 0000876343 · Accession: 0001493152-21-006273
AI Filing Summary & Sentiment
File numbers found in text: 333-254167
Letter
VIA EDGAR
March 17, 2021
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Attn: Jordan Metoyer
Tim Buchmiller
RE: Lineage Cell Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 11, 2021
File No. 333-254167
To Whom It May Concern:
Lineage Cell Therapeutics, Inc., a California corporation (the “Company”), respectfully requests pursuant to Rule 461 under the Securities Act of 1933, as amended, that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-254167) be accelerated and that it be declared effective on March 19, 2021 at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.
Sincerely,
/s/
Brian M. Culley
Show Raw Text
CORRESP
1
filename1.htm
VIA
EDGAR
March
17, 2021
U.S.
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Attn:
Jordan
Metoyer
Tim
Buchmiller
RE:
Lineage
Cell Therapeutics, Inc.
Registration
Statement on Form S-3
Filed
March 11, 2021
File
No. 333-254167
To
Whom It May Concern:
Lineage
Cell Therapeutics, Inc., a California corporation (the “Company”), respectfully requests pursuant to
Rule 461 under the Securities Act of 1933, as amended, that the effective date of the Company’s Registration Statement on
Form S-3 (File No. 333-254167) be accelerated and that it be declared effective on March 19, 2021 at 4:00 p.m. Eastern Time, or
as soon as practicable thereafter.
Sincerely,
/s/
Brian M. Culley
Chief
Executive Officer
cc:
Chase
Leavitt, General Counsel, Lineage Cell Therapeutics, Inc.
Steven
M. Przesmicki, Esq., Cooley LLP